GlycoFi’s proprietary protein expression technology allows us, and our partners, to optimize the exact sugar (glycan) structure of a given therapeutic protein – this can dramatically improve the pharmaceutical attributes of a drug and enhance its therapeutic profile. For example, we are working with our partners on discovery projects that include:
 
• increasing the serum half-life of therapeutic proteins
• increasing the effector function of monoclonal antibodies through selection of
  specific glycan structures which increase binding to Fc receptors
• targeting proteins to specific tissues to enhance their bioavailability
 
Proteins rarely exist in nature with pharmaceutical properties that are suitable for commercialization; GlycoFi’s technology can help you turn a good protein into a great drug.